Proceedings PaperRole of Pharmacogenetics of Immunosuppressive Drugs in Organ TransplantationThervet, Eric MD, PhD*†; Anglicheau, Dany MD, PhD*†; Legendre, Christophe MD*; Beaune, Philippe PhD†Author Information From the *Service de Transplantation Rénale, Hôpital Necker, Paris, France; and †INSERM UMR 775, Centre Universitaire des Saints-Pères, Paris, France. Received for publication September 13, 2007; accepted December 6, 2007. Correspondence: Eric Thervet, MD, PhD, Service de Transplantation Rénale, Hôpital Necker, 149 rue de Sèvres, 75015 Paris, France (e-mail:firstname.lastname@example.org). Therapeutic Drug Monitoring: April 2008 - Volume 30 - Issue 2 - p 143-150 doi: 10.1097/FTD.0b013e31816babef Buy Metrics Abstract The promising role of pharmacogenetics in the attempt to elucidate the inherited basis of differences between individual responses to drugs lies in its potential ability to identify the right drug and dose for each patient. Because immunosuppressive treatments are concentration-critical drugs, therapeutic drug monitoring is mandatory for most of them. After the description of the metabolic pathways of these drugs, the discovery of gene polymorphism has led to the hypothesis that these polymorphisms may be predictive of both pharmacokinetic and pharmacodynamic outcomes after transplantation. In this review, the authors describe the current knowledge regarding gene polymorphisms of metabolizing enzymes and transporters of immunosuppressive drugs. The authors also describe the future development of pharmacogenetics, which could help to better define the correct drug to use, the choice of an adequate initial dose, and the individualization of the risk associated with the use of such drugs after organ transplantation. © 2008 Lippincott Williams & Wilkins, Inc.